RecruitingNCT03413982
Bladder Cancer Longitudinal Biorepository for Development of Novel Therapeutics/Biomarkers
Sponsor
University of Kansas Medical Center
Enrollment
1,000 participants
Start Date
Nov 2, 2017
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of this study is to create a registry, which is a "bank" of information about patients who have had similar medical conditions and treatments. The registry will be used by researchers to learn more about long term outcome of patients with bladder cancer, how bladder cancer tissues are related to tumor development, recurrence and survival.
Eligibility
Min Age: 18 Years
Inclusion Criteria2
- Patients who present to clinic with presumed bladder cancer or have a diagnosis of bladder cancer are eligible to participate
- Patients can participate in any additional research studies during the patients' participation within this protocol.
Exclusion Criteria1
- Patients who do not have presumed bladder cancer will not be eligible
Interventions
OTHERRegistry
Patient registry
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03413982
Related Trials
Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease
NCT000268841 location
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
NCT0712999379 locations
Bio Clinical Collection of Urothelial Carcinoma
NCT049704721 location
Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer
NCT074754031 location
ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
NCT0697316127 locations